May 17, 2016 — An interdisciplinary Johns Hopkins University team has developed a non-invasive 3-D virtual heart assessment tool to help doctors determine whether a particular patient faces the highest risk of a life-threatening arrhythmia.

Macadamian Technologies, a user experience research, design and software development firm, recently announced the completion of a comprehensive usability test of Siemens Acuson S3000 ultrasound system, HELX Evolution with Touch Control.

The U.S. Department of Health and Human Services (HHS) released two funding opportunities from the Office of the National Coordinator for Health Information Technology (ONC), designed to expand use of common standards supporting the sharing of health information.

4Tech Inc. announced its partnership with Jean-Claude Laborde, M.D., as a research and development (R&D) and clinical advisor focused on fast-forwarding the TriCinch Generation Two and Generation Three programs.

At the 96th American Association for Thoracic Surgery (AATS) Annual Meeting, investigators presented the results of a long-term study of patients who underwent mitral valve (MV) repair.


May 16, 2016 — The largest observational study of percutaneous transfemoral transcatheter aortic valve replacement (TAVR) demonstrated that moderate sedation use is associated with improved patient outcomes, including lower 30-day mortality and shorter hospital stays, as compared to traditional general anesthesia. This STS/ACC TVT Registry analysis was presented as a late-breaking clinical trial at the 2016 Society for Cardiovascular Angiography and Interventions (SCAI) annual meeting. 

May 16, 2016 — Cardinal Health announced it has entered into a distribution agreement with Biosensors that enables Cordis, Cardinal Health’s interventional vascular business, to sell Biosensors’ coronary stent portfolio. Cordis will sell Biosensors’ coronary stents in select countries in Europe, the Middle East, Africa, Australia and New Zealand.

May 16,  2016 — Patients treated with processed autologous adipose-derived regenerative cells (ADRCs) injected into the heart muscle demonstrated symptomatic improvement and a trend towards lower rates of heart failure hospitalizations and angina, despite no improvement in left ventricle ejection fraction (LVEF) or ventricular volumes. The ATHENA trial results were presented as a late-breaking clinical trial at the 2016 Society for Cardiovascular Angiography and Interventions (SCAI) annual meeting. 

May 16, 2016 – To work towards a better method of diagnosis and treatment of congestive heart failure (CHF), Peter Eckman, M.D., with the Minneapolis Heart Institute Foundation (MHIF) is an investigator leading the SMILE (Sensible Medical Innovations Lung fLuid status monitor allows rEducing readmission rate of heart failure patients) study at Abbott Northwestern Hospital, Minneapolis. This study will involve the use of the SensiVest, a product developed by Sensible Medical Innovations, headquartered in Israel.

May 16, 2016 — A study using a stem cell therapy to treat challenging refractory angina (RA) patients demonstrated promising results, including improvement exercise time, reduced angina and reduced mortality. The RENEW results were presented as a late-breaking clinical trial at the 2016 Society for Cardiovascular Angiography and Interventions (SCAI) annual meeting.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now